PE20231941A1 - Compuestos de oxoisoindolina sustituidos con piridinilo - Google Patents
Compuestos de oxoisoindolina sustituidos con piridiniloInfo
- Publication number
- PE20231941A1 PE20231941A1 PE2023002812A PE2023002812A PE20231941A1 PE 20231941 A1 PE20231941 A1 PE 20231941A1 PE 2023002812 A PE2023002812 A PE 2023002812A PE 2023002812 A PE2023002812 A PE 2023002812A PE 20231941 A1 PE20231941 A1 PE 20231941A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- oxoisoindoline
- pyridinyl substituted
- methylnicotinonitrile
- dioxopiperidin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical group [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- JIRKNMRIEJWARS-UHFFFAOYSA-N CC(C=C(C(CN1C(CCC(N2)=O)C2=O)=C2)C1=O)=C2C(C=C1C)=NC(N)=C1C#N Chemical compound CC(C=C(C(CN1C(CCC(N2)=O)C2=O)=C2)C1=O)=C2C(C=C1C)=NC(N)=C1C#N JIRKNMRIEJWARS-UHFFFAOYSA-N 0.000 abstract 1
- JNQZDBAKBFBIII-UHFFFAOYSA-N CC1=CC(C(C(C)=C2CN3C(CCC(N4)=O)C4=O)=CC=C2C3=O)=NC(N)=C1C#N Chemical compound CC1=CC(C(C(C)=C2CN3C(CCC(N4)=O)C4=O)=CC=C2C3=O)=NC(N)=C1C#N JNQZDBAKBFBIII-UHFFFAOYSA-N 0.000 abstract 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 102100037796 Zinc finger protein Helios Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- -1 pyridinyl-substituted oxoisoindoline Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula I, o una sal del mismo, en donde: R1 es NH2 o NH(CH3); cada R2 es independientemente F, Cl, CN, alquilo C1-C4, entre otros; cada R4 es independientemente F, Cl, CH3, CH2F, entre otros; R6 es hidrogeno, alquilo C1-C2 o fluoroalquilo C1-C2; m es 0 a 3; n es 0 a 3; con la condicion de que cuando R6 es hidrogeno m es 1 a 3. Son compuestos especificos: 2-amino-6-(2-(2,6-dioxopiperidin-3-il)-4-metil-1 oxoisoindolin-5-il)-4-metilnicotinonitrilo, 2-amino-6-(2-(2,6-dioxopiperidin-3-il)-6-metil-1-oxoisoindolin-5-il)-4-metilnicotinonitrilo, entre otros. Tambien se refiere a una composicion farmaceutica. Los compuestos de la invencion son derivados de oxoisoindolina sustituidos con piridinilo que inhiben la proteina Helios, siendo utiles en el tratamiento de trastornos proliferativos tales como cancer e infecciones virales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202111016193 | 2021-04-06 | ||
| IN202111022098 | 2021-05-17 | ||
| PCT/US2022/023387 WO2022216644A1 (en) | 2021-04-06 | 2022-04-05 | Pyridinyl substituted oxoisoindoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231941A1 true PE20231941A1 (es) | 2023-12-05 |
Family
ID=81385129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002812A PE20231941A1 (es) | 2021-04-06 | 2022-04-05 | Compuestos de oxoisoindolina sustituidos con piridinilo |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11718601B2 (es) |
| EP (1) | EP4320112B1 (es) |
| JP (1) | JP2024515243A (es) |
| KR (1) | KR20230165815A (es) |
| AR (1) | AR125298A1 (es) |
| AU (1) | AU2022253242A1 (es) |
| BR (1) | BR112023020077A2 (es) |
| CA (1) | CA3214244A1 (es) |
| CL (1) | CL2023002966A1 (es) |
| CO (1) | CO2023013321A2 (es) |
| DK (1) | DK4320112T3 (es) |
| ES (1) | ES3035755T3 (es) |
| FI (1) | FI4320112T3 (es) |
| HR (1) | HRP20250796T1 (es) |
| IL (1) | IL307343A (es) |
| LT (1) | LT4320112T (es) |
| MX (1) | MX2023011715A (es) |
| PE (1) | PE20231941A1 (es) |
| PL (1) | PL4320112T3 (es) |
| PT (1) | PT4320112T (es) |
| RS (1) | RS66982B1 (es) |
| SI (1) | SI4320112T1 (es) |
| SM (1) | SMT202500281T1 (es) |
| TW (1) | TWI867287B (es) |
| WO (1) | WO2022216644A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| KR20250138280A (ko) * | 2023-02-08 | 2025-09-19 | 셀진 코포레이션 | 조작된 단백질의 선택적 분해를 위한 화합물 및 조성물 |
| TW202525802A (zh) * | 2023-09-02 | 2025-07-01 | 美商必治妥美雅史谷比公司 | 經取代之苯基氧代㗁唑基哌啶二酮化合物 |
| WO2025199379A1 (en) | 2024-03-22 | 2025-09-25 | Bristol-Myers Squibb Company | Novel fak degrader compounds and uses thereof |
| WO2025226767A1 (en) * | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| WO2025234888A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| WO2025234887A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT925294E (pt) | 1996-07-24 | 2003-04-30 | Celgene Corp | 2-(2,6-dioxopiperidin-3-il)-ftalimidas e -1-oxoisoindolinas substituidas e metodo de reducao dos niveis de tnf-alfa |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| AU2002323063B2 (en) | 2001-08-06 | 2007-11-08 | Entremed, Inc. | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US7812135B2 (en) | 2005-03-25 | 2010-10-12 | Tolerrx, Inc. | GITR-binding antibodies |
| ES2401482T3 (es) | 2005-05-10 | 2013-04-22 | Incyte Corporation | Moduladores de la indolamina 2,3-dioxigenasa y métodos de uso de los mismos |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| TWI382974B (zh) | 2005-12-20 | 2013-01-21 | 英塞特公司 | 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物 |
| EP2064207B1 (en) | 2006-09-19 | 2013-11-06 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| AU2008275589B2 (en) | 2007-07-12 | 2013-11-21 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| SMT202400136T1 (it) | 2008-12-09 | 2024-05-14 | Hoffmann La Roche | Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t |
| JP5561577B2 (ja) | 2009-07-01 | 2014-07-30 | 国立大学法人 名古屋工業大学 | 光学活性３’−フルオロサリドマイド誘導体の製造方法 |
| EP3023438B1 (en) | 2009-09-03 | 2020-03-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| NZ599516A (en) | 2009-12-10 | 2013-11-29 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| CN105481983B (zh) | 2010-09-09 | 2021-09-03 | 辉瑞公司 | 4-1bb结合分子 |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| SMT202000561T1 (it) | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| CA2853889A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| US9822098B2 (en) | 2015-05-22 | 2017-11-21 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| HUE054149T2 (hu) | 2015-06-04 | 2021-08-30 | Arvinas Operations Inc | Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| AU2017232906B2 (en) | 2016-03-16 | 2022-03-31 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Small molecules against cereblon to enhance effector T cell function |
| CA3020275A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Mdm2 protein degraders |
| WO2017185034A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 8 (cdk8) by conjugation of cdk8 inhibitors with e3 ligase ligand and methods of use |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| AU2017326171B2 (en) | 2016-09-13 | 2021-12-09 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as BET protein degraders |
| PL3526202T3 (pl) | 2016-10-11 | 2025-04-28 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
| KR20230127371A (ko) | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| CN114656452B (zh) | 2016-12-01 | 2023-01-17 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| CA3043938A1 (en) | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| CN117510491A (zh) | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| BR112019012682A2 (pt) | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | moléculas quiméricas visando a proteólise de egfr e métodos associados de uso |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| IL321733A (en) | 2017-10-18 | 2025-08-01 | Novartis Ag | Compositions and methods for selective degradation of proteins |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| WO2019191112A1 (en) * | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| US11191769B2 (en) | 2018-06-13 | 2021-12-07 | Biotheryx, Inc. | Fused thiophene compounds |
| CA3103385A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3119343C (en) * | 2018-11-13 | 2024-01-16 | Biotheryx, Inc. | Substituted isoindolinones |
| CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
| EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
| JP7488826B2 (ja) | 2019-02-15 | 2024-05-22 | ノバルティス アーゲー | 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| CN113710661B (zh) | 2019-04-02 | 2022-11-22 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
-
2022
- 2022-04-05 EP EP22718513.9A patent/EP4320112B1/en active Active
- 2022-04-05 JP JP2023561684A patent/JP2024515243A/ja active Pending
- 2022-04-05 TW TW111112957A patent/TWI867287B/zh active
- 2022-04-05 PL PL22718513.9T patent/PL4320112T3/pl unknown
- 2022-04-05 AR ARP220100840A patent/AR125298A1/es unknown
- 2022-04-05 KR KR1020237037708A patent/KR20230165815A/ko active Pending
- 2022-04-05 MX MX2023011715A patent/MX2023011715A/es unknown
- 2022-04-05 PE PE2023002812A patent/PE20231941A1/es unknown
- 2022-04-05 AU AU2022253242A patent/AU2022253242A1/en active Pending
- 2022-04-05 FI FIEP22718513.9T patent/FI4320112T3/fi active
- 2022-04-05 SI SI202230144T patent/SI4320112T1/sl unknown
- 2022-04-05 WO PCT/US2022/023387 patent/WO2022216644A1/en not_active Ceased
- 2022-04-05 HR HRP20250796TT patent/HRP20250796T1/hr unknown
- 2022-04-05 BR BR112023020077A patent/BR112023020077A2/pt unknown
- 2022-04-05 ES ES22718513T patent/ES3035755T3/es active Active
- 2022-04-05 IL IL307343A patent/IL307343A/en unknown
- 2022-04-05 US US17/713,598 patent/US11718601B2/en active Active
- 2022-04-05 SM SM20250281T patent/SMT202500281T1/it unknown
- 2022-04-05 LT LTEPPCT/US2022/023387T patent/LT4320112T/lt unknown
- 2022-04-05 RS RS20250660A patent/RS66982B1/sr unknown
- 2022-04-05 PT PT227185139T patent/PT4320112T/pt unknown
- 2022-04-05 CA CA3214244A patent/CA3214244A1/en active Pending
- 2022-04-05 DK DK22718513.9T patent/DK4320112T3/da active
-
2023
- 2023-06-08 US US18/331,348 patent/US20230303527A1/en not_active Abandoned
- 2023-10-04 CL CL2023002966A patent/CL2023002966A1/es unknown
- 2023-10-05 CO CONC2023/0013321A patent/CO2023013321A2/es unknown
-
2024
- 2024-06-25 US US18/740,857 patent/US20240376082A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023002966A1 (es) | 2024-02-23 |
| SI4320112T1 (sl) | 2025-09-30 |
| KR20230165815A (ko) | 2023-12-05 |
| EP4320112A1 (en) | 2024-02-14 |
| US20220324840A1 (en) | 2022-10-13 |
| BR112023020077A2 (pt) | 2023-11-14 |
| TWI867287B (zh) | 2024-12-21 |
| JP2024515243A (ja) | 2024-04-08 |
| CO2023013321A2 (es) | 2023-10-19 |
| AR125298A1 (es) | 2023-07-05 |
| RS66982B1 (sr) | 2025-07-31 |
| US20240376082A1 (en) | 2024-11-14 |
| MX2023011715A (es) | 2023-10-12 |
| WO2022216644A1 (en) | 2022-10-13 |
| DK4320112T3 (da) | 2025-08-18 |
| SMT202500281T1 (it) | 2025-09-12 |
| IL307343A (en) | 2023-11-01 |
| LT4320112T (lt) | 2025-07-10 |
| TW202304881A (zh) | 2023-02-01 |
| US11718601B2 (en) | 2023-08-08 |
| PT4320112T (pt) | 2025-07-07 |
| FI4320112T3 (fi) | 2025-07-25 |
| ES3035755T3 (en) | 2025-09-08 |
| EP4320112B1 (en) | 2025-05-14 |
| PL4320112T3 (pl) | 2025-07-21 |
| CA3214244A1 (en) | 2022-10-13 |
| US20230303527A1 (en) | 2023-09-28 |
| AU2022253242A1 (en) | 2023-11-23 |
| HRP20250796T1 (hr) | 2025-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231941A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| PE20231207A1 (es) | Derivados indolicos como inhibidores de ras en el tratamiento del cancer | |
| PE20201202A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| PE20221264A1 (es) | Inhibidores de egfr | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20210129A1 (es) | Compuestos de 4-azaindol | |
| PE20200758A1 (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 | |
| PE20210373A1 (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| PE20191260A1 (es) | Compuestos inhibidores del vih | |
| MX2022007369A (es) | Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| PE20171329A1 (es) | Agentes inmunorreguladores | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| PE20141828A1 (es) | 6-alquinilo piridinas como mimeticos smac | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| PE20091524A1 (es) | Derivados de 2-aminopirimidina | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| PE20191082A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| PE20090216A1 (es) | Compuestos triazolil aminopirimidina |